scispace - formally typeset
H

Hong Liu

Researcher at Shandong University

Publications -  2349
Citations -  79103

Hong Liu is an academic researcher from Shandong University. The author has contributed to research in topics: Medicine & Chemistry. The author has an hindex of 100, co-authored 1905 publications receiving 57561 citations. Previous affiliations of Hong Liu include Shanghai University & Guangzhou University.

Papers
More filters
Journal ArticleDOI

Ultrasonic-driven electrical signal-iron ion synergistic stimulation based on piezotronics induced neural differentiation of mesenchymal stem cells on FeOOH/PVDF nanofibrous hybrid membrane

TL;DR: A novel strategy is provided for inducing neural differentiation of rat bone-marrow-derived mesenchymal stem cells via wireless stimulation with piezotronic effect, which is of great significance in clinical and neural tissue engineering.
Journal ArticleDOI

Three-dimensional evaluation of upper anterior alveolar bone dehiscence after incisor retraction and intrusion in adult patients with bimaxillary protrusion malocclusion

TL;DR: For adult patients with bimaxillary protrusion, mechanobiological response of anterior alveolus should be taken into account during incisor retraction and intrusion and Pursuit of maximum anchorage might lead to upper anteriorAlveolar bone loss.
Journal ArticleDOI

Efficient mesh motion using radial basis functions with volume grid points reduction algorithm

TL;DR: An algorithm for volume points reduction based on a wall distance based restricting function which is added to the formulation of the RBF based interpolation and the computational requirement of the proposed procedure is reduced evidently compared with the standard procedure.
Journal ArticleDOI

TIPE2 sensitizes osteosarcoma cells to cis-platin by down-regulating MDR1 via the TAK1- NF-κB and - AP-1 pathways.

TL;DR: Investigation showed that overexpression of TIPE2 effectively inhibited MDR1 expression and greatly sensitized osteosarcoma cells to cis‐platin, both in vivo and in vitro, and may be a novel target in osteosARcoma therapy.
Journal ArticleDOI

Frequent genomic alterations and better prognosis among young patients with non-small-cell lung cancer aged 40 years or younger.

TL;DR: Young patients are associated with an increased likelihood of gene mutations and can receive a better prognosis when patients harboring gene mutations are treated with EGFR-TKIs or ALK inhibitors.